The racemic 5-HT3 receptor antagonist, zacopride (10-l00pgkg-', i.m.) evoked an emetic response in ferrets. This property appeared to reside totally in the S-enantiomer which also produced emesis over the same dose range. This emesis could be prevented by pretreatment with ondansetron (1 mg kg -, i.m.) or by R-zacopride (100,ug kg-1, i.m.). In urethane-anaesthetized ferrets, S-zacopride (0.3 pg kg-i.v.) evoked a profound Bezold-Jarisch reflex which was blocked by both ondansetron (30pgkg-1, i.v.) and by Rzacopride (l00jug kg-1, i.v.). These results suggest that, in the ferret, S-zacopride possesses 5-HT3 receptor agonist properties which may be responsible for the emetic effect. In contrast R-zacopride does not appear to possess 5-HT3 receptor agonist properties in this species.
Introduction Zacopride (4-amino-N-[1-azabicyclo(2.2.2)oct-3-yl]-5-chloro-2-methoxybenzamide{E}-2butenedioate) is a racemic compound described as a potent and selective 5-HT3 receptor antagonist (Smith et al., 1988a) . Racemic zacopride (hereafter referred to as zacopride) has been shown to be an effective anti-emetic agent against the emesis induced by cytotoxins or radiation in dogs, cats, non-human primates and ferrets (Costall et al., 1987; Dubois et al., 1988; King et al., 1988; Smith et al., 1988b; . Recently, zacopride has been shown to be emetogenic following administration of 0.003-0.3mg kg 'p.o. or i.v. to ferrets (King, 1990) . We have compared the 5-HT3 receptor antagonist properties of both stereoisomers of zacopride in ferrets anaesthetized with urethane and have investigated the mechanism of its emetogenic properties in conscious ferrets.
Methods Zacopride and -its enantiomers in anaesthetized ferrets Female fitch or albino ferrets (0.8-1.3 kg) were anaesthetized with urethane (1.0-1.5 gkg-', i.p.). Both jugular veins were cannulated for the administration of drugs and blood pressure was recorded from a carotid artery. Reproducible, submaximal Bezold-Jarisch (B-J) reflex responses to one dose of 5-hydroxytryptamine (5-HT) (10 or 30/ugkg-', i.v.) were obtained at 10 min intervals and this dose of 5-HT used throughout the experiment. The B-J reflex was measured as the instantaneous increase in heart period (HP, i.e. beat to beat interval averaged over 4 consecutive beats) following the intravenous bolus administration of 5-HT. Control values were obtained by averaging the HP over 10 consecutive beats.
Increasing doses of zacopride (0.3-100 pg kg-', i.v.) were administered and the response to 5-HT retested 10min after each dose. The next dose of zacopride was administered immediately after the transient response to 5-HT. Additional studies investigated the profile of activity of the stereoisomers of zacopride (see results section). Statistical analysis was by 2-way analysis of variance. Emesis studies Adult female albino or fitch ferrets (0.8-1.3 kg) were placed singly in an observation cage 30min before drug administration with free access to food and water. Drugs were dissolved in sterile isotonic saline (standard volume 0.4ml) and administered intramuscularly, into the biceps femoris of Author for correspondence. the hind limb. In all experiments in which a premedicant drug was given, a 15 min pretreatment time was allowed and the two injections were made contralaterally. The animals were observed for 60 min during which time the presence or absence of retching and/or vomiting was recorded in 5 min time bins, as were any other overt effects. The number of emetic events (i.e. retches or vomits) was not recorded.
Results
The effect of zacopride and its stereoisomers in the anaesthetised ferret A small change in HP (approx. 15% of the control HP) generally accompanied the administration of a bolus of cold saline (0.4 ml i.v.), hence a value of 85% inhibition of the B-J reflex evoked by 5-HT was considered to be a complete block of the response. 5-HT (lOpgkg-') evoked a marked B-J reflex in the anaesthetized ferret with a mean increase in HP of 703 (s.e. 113 ms, n = 4) which was blocked by zacopride (3ugkg-', i.v., P < 0.001, n = 4).
Administration of zacopride (0.1-3.0pugkg-1, i.v.) itself evoked a marked 'B-J-like' effect in these experiments, i.e. a transient but profound bradycardia, hypotension and apnoea, (data not shown) and this phenomenon was subsequently investigated using the two stereoisomers of zacopride.
S-zacopride (0.3 pgkg-, i.v.) evoked 'B-J-like' response with a mean increase in HP of 7232 (s.e. 3530ms, n = 4). A lower dose of S-zacopride (0.1pg kg-1, i.v.) did not consistently produce a 'B-J-like' effect. In these experiments the B-J reflex to 5-HT (lOpgkg-1, i.v.) obtained 10min after administration of S-zacopride (0.3 pgkg-', i.v.) was not statistically significantly different from the predose response to the same dose of 5-HT (mean change in HP, predose = 465 (s.e. 30ms) and post S-zacopride = 531 (s.e. 51 ms)). Ten minutes after administration of the selective 5-HT3 receptor antagonist, ondansetron (30 pugkg-1, i.v. n = 4) however, the responses to both 5-HT and S-zacopride were blocked (i.e. > 85% inhibition, P < 0.001). Administration of R-zacopride (0.1-lO00pgkg-1, i.v.) did not produce any discernible effects on HP.
In a separate series of experiments, after obtaining reproducible B-J responses to both 5-HT (lOpgkg-1, i.v.) and to S-zacopride (0.3,pg kg-', i.v.), incremental doses of Rzacopride (1-l 00pg kg-1, i.v.) were administered every 10 min.
The response to 5-HT was tested 5 min after each dose of Rzacopride and the response to S-zacopride tested 5 min after 5-HT. R-zacopride produced a dose-dependent attenuation of both the 5-HT-and S-zacopride-induced B-J responses, the highest dose of R-zacopride (100ugkg-1, i.v.) producing a 74% and 98% attenuation respectively (P < 0.05).
Emesis studies Administration of either zacopride or Szacopride (1 pg kg-1, i.m., n = 2 and n = 4 respectively) produced no adverse effects. Zacopride (lOpgkg-1, i.m., n = 7) was emetogenic in all of the animals studied whereas lOOI g kg-1, i.m. (n = 3) produced emesis in only one animal. Similarly, S-zacopride (lOpgkg-', i.m.) produced emesis in 4/6 animals and in 3/4 animals following 100 pgkg-', i.m.
Both zacopride and S-zacopride were sedative at lOOpugkg-1, i.m. R-zacopride (10 or lOOpgkg-', i.m., n = 4) was not emetogenic although one ferret vomited following R-zacopride (1000 jug kg-', i.m., n = 4).
Additional experiments examined the effects of pretreatment with ondansetron (100 or 1000lgkg-1, i.m., n = 4 per group). Following ondansetron (lOOugkg-1) no emesis was observed in response to administration of zacopride (10pgkg-1, i.m.) and although the mean latency to the first emetic episode following S-zacopride (10ug kg-1, i.m.) was increased from 10min to 21 min, all the animals retched and/or vomited. No emesis was observed following S-zacopride (lOpugkg-1, i.m.) in animals pretreated with either ondansetron (lOOOpgkg 1) or R-zacopride (100 pg kg-', i.m.). Pretreatment with atropine (100gkg-1, i.m.) did not prevent the emesis evoked by either zacopride (lOpgkg-1, i.m., n = 3) or S-zacopride (10pigkg-1, i.m., n = 2). A higher dose of atropine (1 mg kg-1 i.m., n = 2), despite producing marked sedation, did not prevent zacopride-(lOpgkg-1, i.m.) induced emesis.
Discussion We have previously demonstrated that both enantiomers of zacopride behave as 5-HT3 receptor antagonists in the rat (Middlefell et al., 1990) . Experiments in anaesthetized ferrets demonstrated that intravenous administration of S-zacopride evoked a marked B-J reflex which could be blocked by either ondansetron or by R-zacopride. Higher intravenous doses of S-zacopride were not tested on the assumption that the profound bradycardia and apnoea which was produced by 0.3 pgkg-t would prove fatal were the dose to be increased (although this remains to be tested). At no time was a B-J reflex elicited by intravenous administration of R-zacopride. We have therefore been unable to demonstrate any 5-HT3 receptor antagonist effects of S-zacopride in the ferret. In addition it would seem that in this species, the 5-HT3 antagonist properties of zacopride are conferred by the R-enantiomer.
These experiments have demonstrated that emesis is evoked by zacopride following intramuscular administration to ferrets. This emetic action was produced by S-zacopride, but not by R-zacopride over the same dose-range. At a substantially higher dose, R-zacopride (1mgkg-', i.m.) evoked an emetic response in one animal, the reason for this is unknown and no attempt was made to block it. Other workers (King, 1990) however, have reported emesis following very high doses of granisetron in the ferret and suggest that this may be a non-5-HT3-mediated effect. Emesis produced by both zacopride and S-zacopride was prevented by either the selective 5-HT3 antagonist ondansetron, or by R-zacopride. It is noteworthy that the dose of ondansetron required to prevent zacopride-induced emesis only lengthened the latency to vomit following the same dose of S-zacopride. This may be explained by the fact that, assuming a 1:1 mixture of the enantiomers, an equivalent dose of S-zacopride would be half that of the racemate.
These results suggest that zacopride has 5-HT3 receptor agonist activity in ferrets and that this property resides primarily in the S-enantiomer. Zacopride, like many other benzamides, has been reported to possess 5-HT4 receptor agonist effects but we do not consider this to be relevant to its emetogenic properties since ondansetron, which is not believed to be an antagonist of 5-HT4 receptors (Clarke et al., 1989 ) prevents the emesis.
In conclusion, the S-enantiomer of zacopride appears to possess 5-HT3 receptor agonist properties in the ferret which may be responsible for its emetogenic effects.
